Anticancer activity of undecapeptide analogues derived from antimicrobial peptide, brevinin-1EMa
Su-Jin Kang1, Hye-Young Ji, Bong-Jin Lee
1Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Korea.
Abstract:
In spite of great advances in cancer therapy, cancer remains the major cause of death throughout the world. The increasing resistance of cancer cells towards current anticancer drugs requires development of anticancer agents with a new mode of action. Some antimicrobial peptides have become therapeutic candidates as new anticancer agents. As part of an effort to develop new antimicrobial and/or anticancer agents from natural peptides with low molecular weights, we have investigated the shortest bioactive analogues, which were derived from a 24-residue antimicrobial peptide, Brevinin-1EMa. Recently, we found four bioactive undecapeptides derived from a cationic, amphipathic α-helical, 11-residue peptide (named herein GA-W2: FLGWLFKWASK-NH(2)) (Won et al., 2011). In order to identify the potential of these peptides as anticancer agents, we investigated the anticancer activity of four undecapeptides against seven tumor cell lines such as A498 (kidney), A549 (lung), HCT116 (colon), MKN45 (stomach), PC-3 (prostate), SK-MEL-2 (skin) and SK-OV-3 (ovary). GA-K4 (FLKWLFKWAKK-NH(2)), which had the most potent antimicrobial activity of the four undecapeptides, also exhibited the most potent anticancer activity and synergistic effect in combination with doxorubicin. Therefore, GA-K4 peptide may be a potentially useful candidate as an anticancer peptide agent.
Insights
Researchers explored new anticancer agents derived from antimicrobial peptides. The peptide GA-K4 showed potent anticancer activity and synergistic effects with doxorubicin, suggesting its potential as a novel cancer therapeutic.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Cancer remains a leading global cause of death, necessitating novel therapeutic strategies due to increasing drug resistance.
- Antimicrobial peptides are emerging as promising anticancer agents with unique mechanisms of action.
- Developing low molecular weight, natural peptide-derived agents offers a new avenue for cancer treatment.
Purpose of the Study:
- To investigate the anticancer potential of novel undecapeptides derived from the antimicrobial peptide Brevinin-1EMa.
- To evaluate the efficacy of these peptides against a panel of human tumor cell lines.
- To identify lead peptide candidates for further development as anticancer agents.
Main Methods:
- Synthesis and characterization of four bioactive undecapeptides derived from a parent antimicrobial peptide.
- In vitro anticancer activity screening against seven human tumor cell lines (A498, A549, HCT116, MKN45, PC-3, SK-MEL-2, SK-OV-3).
- Evaluation of synergistic effects of the most potent peptide in combination with doxorubicin.
Main Results:
- The undecapeptide GA-K4 demonstrated the most potent antimicrobial activity among the tested analogs.
- GA-K4 exhibited significant and potent anticancer activity across multiple tumor cell lines.
- A notable synergistic effect was observed when GA-K4 was combined with the chemotherapeutic agent doxorubicin.
Conclusions:
- The peptide GA-K4, derived from Brevinin-1EMa, possesses significant anticancer properties.
- GA-K4 shows promise as a potential anticancer peptide agent, particularly in combination therapy.
- Further research into GA-K4 could lead to the development of novel cancer therapeutics.
Related Concept Videos
01:23Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
01:28Antimicrobial Effectiveness